CD274 and neoplasm: The abovementioned immunostimulatory effects of ALKi in general, such as PD-L1 down-regulation, upregulation of HLA molecules, immunogenetic cell death and increased expression of tumor-associated antigens could further be improved by alcetinib which maintains DC functionality in contrast to crizotinib.